CCDC27 Inhibitors
CCDC27 inhibitors are a diverse set of chemical compounds that indirectly suppress the functional activity of CCDC27 through various signaling pathways and cellular processes. Rapamycin, an mTOR inhibitor, is believed to downregulate pathways involved in cell growth and proliferation, potentially decreasing CCDC27's activity if it is part of this pathway. Similarly, Staurosporine broadly targets kinases that may regulate CCDC27 through phosphorylation, thus the use of this inhibitor could lead to diminished CCDC27 function. LY 294002 and Wortmannin, both PI3K inhibitors, can suppress PI3K/Akt signaling; if CCDC27 operates within this pathway, its activity would be lessened. SB 203580 and U0126, targeting p38 MAP kinase and MEK1/2 respectively, could reduce CCDC27's role in stress response or cell differentiation if it is linked to the MAPK/ERK pathway. Additionally, PD 98059 and SP600125, which inhibit MEK and JNK, could attenuate CCDC27's activity by interfering with respective signaling cascades.
The remaining compounds in the CCDC27 inhibitor group function through diverse mechanisms to impede CCDC27's activity. 6-Cyano-7-nitroquinoxaline-2,3-dione, an AMPA receptor antagonist, could reduce CCDC27's potential involvement in neural signaling pathways by inhibiting excitatory neurotransmission. Brefeldin A disrupts vesicle trafficking, which would impede CCDC27 if it plays a role in vesicle formation or movement. Cyclopamine's inhibition of the Hedgehog signaling could diminish CCDC27's function in cell differentiation processes. Lastly, Mitomycin C, a DNA cross-linker, could result in a decrease in CCDC27's activity by disrupting cell cycle progression. Collectively, these inhibitors could serve to reduce the functional activity of CCDC27 by targeting the specific pathways or processes in which the protein is involved, leading to a comprehensive inhibition of its cellular role.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
As an mTOR inhibitor, Rapamycin would inhibit the mTOR pathway, which is crucial for cell growth and proliferation. If CCDC27 is involved in these processes, Rapamycin-induced mTOR inhibition would diminish CCDC27's functional contributions to cell growth. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor, Staurosporine, can inhibit a broad range of protein kinases. If CCDC27 is regulated by phosphorylation, the inhibition of those kinases could indirectly diminish CCDC27's functional activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
As a PI3K inhibitor, LY 294002 suppresses the PI3K/Akt signaling pathway. If CCDC27 functions are PI3K/Akt-dependent, inhibition by LY 294002 would lead to a decrease in CCDC27's activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 inhibits p38 MAP kinase. If CCDC27 is implicated in stress response pathways modulated by p38, this inhibitor could diminish CCDC27's activity under stress conditions. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK1/2, U0126 would affect the MAPK/ERK pathway. If CCDC27 is involved in signaling cascades related to cell division or differentiation that depend on ERK, its inhibition could lead to reduced CCDC27 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, and by inhibiting PI3K, it would affect downstream signaling. If CCDC27's activity is connected to the PI3K pathway, Wortmannin would diminish its functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of MEK, PD 98059 would inhibit ERK activation. If CCDC27 is part of the ERK pathway, its activity would be diminished by PD 98059. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 would interfere with JNK signaling. If CCDC27 operates within the JNK pathway, its inhibition would lead to decreased CCDC27 activity. | ||||||
6-Cyano-7-nitroquinoxaline-2,3-dione | 115066-14-3 | sc-505104 | 10 mg | $204.00 | 2 | |
An AMPA receptor antagonist, 6-Cyano-7-nitroquinoxaline-2,3-dione could inhibit excitatory neurotransmission. If CCDC27 is associated with neuronal activity, its inhibition by CNQX could decrease its activity in neural pathways. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (ARF), Brefeldin A would disrupt vesicle trafficking. If CCDC27 is involved in vesicle formation or trafficking, its function would be inhibited by Brefeldin A. | ||||||